Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Catalent, Humanigen Expand Lenzilumab Services Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Catalent, Humanigen Expand Lenzilumab Services Pact

Catalent will provide development, manufacturing and commercialization services for Humanigen’s GM-CSF monoclonal antibody being studied in COVID-19.

By: Contract Pharma

Contract Pharma Staff

Catalent and Humanigen, Inc. have expanded their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigen’s Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.

Recent data on the first clinical use of lenzilumab in 12 patients with severe and critical COVID-19 pneumonia, showed the majority had rapid recovery and hospital discharge. A Phase III study is currently underway evaluating hospitalized COVID-19 patients.

To date, Catalent Biologics has provided early-stage development and clinical cGMP drug substance manufacturing for lenzilumab at its facility in Madison, WI to support Humanigen’s ongoing clinical trials across various diseases. Under the expanded partnership, Catalent is also providing clinical supply support for Humanigen’s Phase III potential registration study in COVID-19 from its Philadelphia facility.

Lenzilumab was originally manufactured in Catalent’s Madison facility using Catalent Biologics’ proprietary GPEx cell line development technology. As part of the expanded partnership, Catalent intends to provide additional drug substance clinical supply for Humanigen’s clinical trials, Expanded Access Program (EAP), as well as additional late-stage development and clinical and potential commercial drug substance manufacturing and vial filling at its Madison and Bloomington, IN, sites.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics